Ascendis Pharma
ASND
Market cap $7.59B

126.97 USD

-1.69

1.31%

Updated Oct 22, 10:46 AM EDT

1 day

-1.31%

5 days

-0.41%

1 month

-13.39%

3 months

-6.86%

6 months

-10.65%

Year to date

-0.44%

1 year

45.71%

5 years

18.64%

About: Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Employees: 879

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 19 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

8% more funds holding

Funds holding: 185 [Q1] → 200 (+15) [Q2]

6% more funds holding in top 10

Funds holding in top 10: 16 [Q1] → 17 (+1) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 67

0.45% less ownership

Funds ownership: 105.39% [Q1] → 104.95% (-0.45%) [Q2]

10% less capital invested

Capital invested by funds: $9.19B [Q1] → $8.26B (-$934M) [Q2]

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

See Fund Rankings

Research analyst outlook

19 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$157

24%

upside

Avg. target

$191

51%

upside

High target

$289

128%

upside

19 analyst ratings

19 positive

100%

0 neutral

0%

0 negative

0%

TD Cowen Yaron Werber 64% 1-year accuracy 7 / 11 met price target	26%upside $160	Buy Maintained	21 Oct 2024
B of A Securities Tazeen Ahmad 54% 1-year accuracy 14 / 26 met price target	50%upside $191	Buy Maintained	23 Sept 2024
Wells Fargo Derek Archila 65% 1-year accuracy 15 / 23 met price target	128%upside $289	Overweight Maintained	17 Sept 2024
Citigroup David Lebowitz 52% 1-year accuracy 11 / 21 met price target	63%upside $207	Buy Maintained	17 Sept 2024
Evercore ISI Group Josh Schimmer 66% 1-year accuracy 40 / 61 met price target	61%upside $205	Outperform Maintained	17 Sept 2024

See Analyst Rankings

Financial journalist opinion

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD).

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency.

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions.

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of ADSs at the public offering price, less the underwriting commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Zacks Investment Research

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Ascendis Soars on Encouraging Data From Dwarfism Drug Study

Zacks Investment Research

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024.

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

See News Rankings

Charts implemented using Lightweight Charts™